Bespoke Extracts (BSPK) Change in Accured Expenses (2016 - 2025)
Bespoke Extracts (BSPK) reported Change in Accured Expenses of $48628.0 for Q3 2025, down 58.65% on a YoY basis from $117596.0 in Q3 2024, and down 77.96% sequentially from $220641.0 in Q2 2025.
Bespoke Extracts (BSPK) Change in Accured Expenses (2016 - 2025) Analysis & Trends
Bespoke Extracts (BSPK) has 10 years of Change in Accured Expenses data on file, last reported at $48628.0 in Q3 2025.
- For the quarter ending Q3 2025, Change in Accured Expenses fell 58.65% year-over-year to $48628.0; the trailing twelve-month figure through Sep 2025 stood at $453878.0 (down 26.32% YoY), and the FY2024 full-year result was $505019.0, down 24.11% from the prior year.
- Change in Accured Expenses eased to $48628.0 in Q3 2025, from $220641.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $220641.0 in Q2 2025 to a low of -$53792.0 in Q2 2021.
- A 5-year average of $99891.8 and a median of $94784.5 in 2022 frame the typical range for Change in Accured Expenses.
- Across the five-year window, Change in Accured Expenses tumbled 413.53% in 2021 and jumped 757.31% in 2023, its largest moves.
- Tracing BSPK's Change in Accured Expenses over 5 years: stood at $18266.0 in 2021, then soared by 294.03% to $71973.0 in 2022, then jumped by 80.95% to $130237.0 in 2023, then tumbled by 85.19% to $19285.0 in 2024, then surged by 152.15% to $48628.0 in 2025.
- Business Quant data shows BSPK's Change in Accured Expenses at $48628.0 in Q3 2025, $220641.0 in Q2 2025, and $165324.0 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.46 Bn | 87.60 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.98 Bn | 32.24 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 32.62 Bn | 30.68 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn | -12.70 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.63 Bn | 12.20 Bn | 785.00 Mn | - |
| 10 | Bespoke Extracts | 1.12 Mn | 1.11 Mn | 234,175.00 | 48,628.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 48,628.00 |
| Sep 30, 2025 | 48,628.00 |
| Jun 30, 2025 | 220,641.00 |
| Jun 30, 2025 | 220,641.00 |
| Mar 31, 2025 | 165,324.00 |
| Mar 31, 2025 | 165,324.00 |
| Dec 31, 2024 | 19,285.00 |
| Dec 31, 2024 | 19,285.00 |
| Sep 30, 2024 | 117,596.00 |
| Sep 30, 2024 | 117,596.00 |
| Jun 30, 2024 | 192,096.00 |
| Jun 30, 2024 | 192,096.00 |
| Mar 31, 2024 | 176,042.00 |
| Mar 31, 2024 | 176,042.00 |
| Dec 31, 2023 | 130,237.00 |
| Dec 31, 2023 | 130,237.00 |
| Sep 30, 2023 | 215,588.00 |
| Sep 30, 2023 | 215,588.00 |
| Jun 30, 2023 | 123,356.00 |
| Jun 30, 2023 | 123,356.00 |